A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
Sponsor: Agensys, Inc.
Listed as NCT01672775, this PHASE1 trial focuses on Carcinoma, Renal Cell and Renal Cell Carcinoma With Clear Cell Histology and remains completed. Sponsored by Agensys, Inc., it has been updated 9 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Dec 2024 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Dec 2024 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Dec 2020 [monthly]
Completed PHASE1
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Agensys, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .